Eris Lifesciences Limited announced the approval by its Board of Directors for the acquisition of the Branded Probiotic Products business from Velbiom Probiotics Private Limited. The transaction is structured as a slump sale for a total consideration of INR 50 crore. This strategic move aims to bolster Eris’s portfolio in high-growth therapeutic areas, including metabolic health and gut wellness, integrating Velbiom’s science-driven bio-therapeutics pipeline.
Strategic Acquisition Approved by Board
The Board of Directors of Eris Lifesciences Limited convened on Friday, March 20, 2026, to approve the execution of a Business Transfer Agreement (“BTA”). This agreement facilitates the acquisition of the Branded Probiotic Products division from Velbiom Probiotics Private Limited (VPPL). The acquisition will be completed on a slump sale basis, integrating Velbiom’s specialized portfolio focused on prebiotics and probiotics for metabolic, gut, and women’s health.
Key Transaction Details
The fundamental terms of the deal outline a total consideration payable by Eris Lifesciences Limited to VPPL amounting to INR 50 crore (Indian Rupees Fifty Crore only). The meeting officially commenced at 12:45 P.M. and concluded at 03:15 P.M. on the day of the announcement.
Acquired Business Performance
Details provided regarding the revenue generated by the acquired business over the last three financial periods indicate consistent growth and scale:
- 9M FY26: Rs. 16.02 cr.
- FY25: Rs. 19.64 cr
- FY24: Rs. 17.56 cr
Compliance and Relationship Status
It was confirmed that no shareholding is involved in this transaction, as it is an acquisition of a business as a going concern. Furthermore, the transaction is explicitly stated as not a related party transaction, meaning that arms length assessment and approval were not required for this reason. No special rights, such as the right to appoint directors or restrictive capital structure clauses, were stipulated within the agreement terms.
Source: BSE
